C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment

Diabetes Research and Clinical Practice

Volumn 98, Issue 3, 2012, Pages

  Takabe, Michinori ^a   Matsuda, Tomokazu ^a   Hirota, Yushi ^a   Hashimoto, Naoko ^a   Nakamura, Tomoaki ^a   Sakaguchi, Kazuhiko ^a   Ogawa, Wataru ^a   Seino, Susumu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Early insulin secretion; Glucagon challenge test; Insulinogenic Index; Liraglutide

Indexed keywords

C PEPTIDE; GLUCAGON; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE ACTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; KINETICS; MALE; MIDDLE AGED; RECEPTORS, GLUCAGON;

EID: 84870698890     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.09.036     Document Type: Article

References (19)

1. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
2. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
3. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
4. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
5. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
6. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
7. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012, [Epub ahead of print]. 10.1016/j.diabres.2011.12.015.
8. Kashiwagi A., Kasuga M., Araki E., et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program value. J Diabetes Invest 2012, 3:39-40.
9. Pratley R.E., Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001, 44:929-945.
10. Gastaldelli A., Ferrannini E., Miyazaki Y., et al. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004, 47:31-39.
11. Tanaka Y., Atsumi Y., Matsuoka K., et al. Interesting insulin response to oral glucose load in young Japanese subjects with impaired glucose tolerance. Diabetes Care 2000, 23:710-712.
12. Kosaka K., Kuzuya T., Hagura R. Insulin secretory response in Japanese type 2 (non-insulin-dependent) diabetic patients. Diabetes Res Clin Pract 1994, 24:101-110.
13. Kahn S.E., Lachin J.M., Zinman B., et al. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011, 60:1552-1560.
14. Rasouli N., Kern P.A., Reece E.A., et al. Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E359-E365.
15. Ozaki N., Shibasaki T., Kashima Y., et al. P-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000, 2:805-811.
16. Shibasaki T., Takahashi H., Miki T., et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 2007, 104:19333-19338.
17. Zhang C.L., Katoh M., Shibasaki T., et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009, 325:607-610.
18. Seino S., Shibasaki T., Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 2011, 121:2118-2125.
19. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009, 8:371-385.